Weekly Journal Scan: Effects of oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes and high risk profile
GLP-1RAs are gaining importance as a pillar of the therapeutic strategies in patients with cardiovascular-kidney-metabolic syndrome.2 Indeed, a large body of evidence has shown their role in reducing myocardial fibrosis and cardiac hypertrophy, improving cardiac function and attenuating cardiometabolic dysregulation.3 In addition, GLP-1RAs have been successfully tested in the pharmacological management of overweight and obesity.4 A significant reduction of MACE in subjects treated with GLP-1RAs has been demonstrated in different clinical settings.
Authors
- Giovanna Gallo (ORCID: https://orcid.org/0000-0003-4845-117X)
- Massimo Volpe (ORCID: https://orcid.org/0000-0002-9642-8380)
Institutions
- Azienda Ospedaliera Sant'Andrea (IT)
- IRCCS Ospedale San Raffaele (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- European Heart Journal
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1093/eurheartj/ehaf299
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29